Long-term follow-up for patients treated with Miltenyi CAR T therapies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial focuses on the long-term safety and efficacy of Miltenyi CAR T cell therapies in patients who have previously undergone treatment. It aims to monitor late adverse reactions, serious adverse events, and disease progression over time. The study will track various health outcomes, including the detection of CAR T cell transgenes and any new malignancies, particularly in pediatric patients. Overall survival and disease status will also be assessed to understand the long-term impact of the therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
* Patient has provided informed consent prior to enrollment.

Exclusion Criteria:

* No exclusion criteria

Where it's running

• Charité Universitätsmedizin Berlin
  Berlin, Germany Recruiting
• Universitätsklinikum Münster
  Münster, Germany Recruiting
• Universitätsklinikum Köln
  Cologne, Germany Active not recruiting
• Uniklinikum Erlangen
  Erlangen, Germany Active not recruiting
• Universitätsmedizin Göttingen
  Göttingen, Germany Active not recruiting
• Universitätsklinikum Tübingen
  Tübingen, Germany Active not recruiting

Study contacts

• Principal investigator: Claudia Rössig, Prof. Dr. — Universitätsklinikum Münster
• Study coordinator: Clinical Trial Manager
• Email: clinicaltrials.gov@miltenyi.com
• Phone: +4922048306820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Neoadjuvant and adjuvant immunotherapy for advanced melanoma

  This study is testing if a new type of immunotherapy can help people with advanced melanoma do better before and after surgery.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06295159

• Evaluating new treatments for advanced melanoma with pembrolizumab

  This study is testing new treatment combinations for patients with advanced melanoma who haven't responded to previous therapies to see if they can improve their chances of survival.

  Recruiting at 5 sites Phase 2 Philogen S.p.A. · Hartford, Connecticut and 6 other locations · NCT06284590

• Gene-modified TIL therapy (ADP-TILIL7) for locally advanced or metastatic melanoma

  This study will test whether a patient's own tumor-infiltrating lymphocytes, gene-modified to produce IL-7, can be safely given to adults with unresectable or metastatic melanoma who have progressed after PD-1 therapy.

  Recruiting at 2 sites Phase 1 Herlev Hospital · Herlev and 1 other locations · NCT06204991

• Analyzing PET scans and blood samples in melanoma patients receiving immunotherapy

  This study is testing if early PET scans and blood tests can help predict how well immunotherapy works for people with advanced melanoma.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT06199713

• Assessing KB707 for treating advanced melanoma and solid tumors

  This study is testing a new treatment called KB707, which is a modified virus, to see if it can help adults with advanced melanoma and other solid tumors who haven't had success with regular treatments.

  Recruiting at 15 sites Phase 1/2 Krystal Biotech, Inc. · Los Angeles, California and 14 other locations · NCT05970497

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.